ResearchSafe

Tesamorelin’s VAT loss: promising marker, uncertain performance

Posted by mom984 in GH & Growth Peptides - 18 points, 4 comments.

https://www.ncbi.nlm.nih.gov/books/NBK539136

The NCBI Bookshelf review breaks down the FDA’s stance on tesamorelin – it clearly cuts visceral abdominal fat in HIV‑related lipodystrophy, but the agency admits the real‑world health benefit of that reduction is still up in the air. The paper walks through three trials, all of which excluded anyone on other GH‑secretagogues, and points out that while the biomarker changes are solid, we don’t yet know if they translate into lower cardiovascular risk or better metabolic health.

For me the article feels spot‑on about the hype gap. I’ve tried a low‑dose ipamorelin/CJC‑1295 stack for a few months and noticed a subtle improvement in sleep quality and recovery, but I’ve never seen a dramatic change in waist size. Tesamorelin’s data look cleaner because it’s a pure GHRH analogue, yet the lack of hard outcomes makes me hesitant to recommend it beyond the approved HIV population. The cost and need for daily injections also scream “niche” to me. I’d love to see a longer‑term study that measures hard endpoints like insulin sensitivity or heart health in otherwise healthy folks.

Has anyone here tracked blood work or body‑composition changes on tesamorelin outside of the HIV context? What markers would you monitor to decide if the visceral fat loss is actually worth the effort?

Comments

  • labrat328: As a nurse, I basically live for the data, but this gap between a biomarker and an actual health outcome is a bit concerning... I am still very new to this side of the research world, so I am just trying to wrap my head around the basics. I have been looking into how this might help with recovery for my ultramarathons, but the cost is a huge hurdle. For me, the idea of daily injections just to possibly shift some waist fat seems like a lot of work if we do not know it helps the heart... Has any
  • mom984: I get the data‑first vibe, especially coming from a nursing background – the whole “biomarker vs real outcome” thing really does make you pause. In my short run with ipamorelin/CJC‑1295 I didn’t see any shift in fasting glucose either, just the sleep bump. As for tesamorelin, I haven’t measured glucose personally, but the few anecdotes I’ve heard on here are mixed – a couple of folks said a tiny drop, others no change. If you’re eyeing it for ultra recovery, the injection hassle and price probab
  • dominic_d: actually, the cardiovascular bit is where i get skeptical. for what it is worth, i tried tesamorelin since about a year and my fasting glucose stayed quite stable. but i suspect it could just be my diet. you should talk to a doctor about your insulin sensitivity before starting, because the gh axis is tricky. i dont think the fat loss is worth the cost for athletics.
  • mom984: Interesting you kept your glucose steady for a year – I was hoping to see a trend one way or another. My own diet hasn’t changed much either, so I can’t tease it apart either. I did run a quick fasting insulin check before I started a low‑dose ipamorelin run and it was borderline high, so I’m definitely keeping an eye on that if I ever move to tesamorelin. Thanks for the reminder about getting a doctor in the loop – I’ll book a consult before any next step.

Community discussion - research and educational context only. Not medical advice.